Eberhard Standl

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.6K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

L Rydén, Eberhard Standl, M. Bartnik et al. · European Heart Journal · 2006 · 1.7K citations · Full text

Medicine, Cardiology, Endocrinology +17

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Nikolaus Marx, Massimo Federici, Katharina Schütt et al. · European Heart Journal · 2023 · 1.4K citations · Full text

Medicine, Cardiology, Endocrinology +17

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Bo Åhrén, Ramón Gomis, Eberhard Standl et al. · Diabetes Care · 2004 · 488 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17